TY  - JOUR
A1  - Gentschev, Ivaylo
A1  - Adelfinger, Marion
A1  - Josupeit, Rafael
A1  - Rudolph, Stephan
A1  - Ehrig, Klaas
A1  - Donat, Ulrike
A1  - Weibel, Stephanie
A1  - Chen, Nanhai G.
A1  - Yu, Yong A.
A1  - Zhang, Qian
A1  - Heisig, Martin
A1  - Thamm, Douglas
A1  - Stritzker, Jochen
A1  - MacNeill, Amy
A1  - Szalay, Aladar A.
T1  - Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
JF  - PLoS One
N2  - Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for canine cancer therapy. In this study we describe the establishment of an in vivo model of canine soft tissue sarcoma (CSTS) using the new isolated cell line STSA-1 and the analysis of the virus-mediated oncolytic and immunological effects of two different Lister VACV LIVP1.1.1 and GLV-1h68 strains against CSTS. Cell culture data demonstrated that both tested VACV strains efficiently infected and destroyed cells of the canine soft tissue sarcoma line STSA-1. In addition, in our new canine sarcoma tumor xenograft mouse model, systemic administration of LIVP1.1.1 or GLV-1h68 viruses led to significant inhibition of tumor growth compared to control mice. Furthermore, LIVP1.1.1 mediated therapy resulted in almost complete tumor regression and resulted in long-term survival of sarcoma-bearing mice. The replication of the tested VACV strains in tumor tissues led to strong oncolytic effects accompanied by an intense intratumoral infiltration of host immune cells, mainly neutrophils. These findings suggest that the direct viral oncolysis of tumor cells and the virus-dependent activation of tumor-associated host immune cells could be crucial parts of anti-tumor mechanism in STSA-1 xenografts. In summary, the data showed that both tested vaccinia virus strains and especially LIVP1.1.1 have great potential for effective treatment of CSTS.
KW  - breast-tumors
KW  - animal-model
KW  - nude-mice
KW  - cell-line
KW  - in-vitro
KW  - glv-1h68
KW  - cancer
KW  - virotherapy
KW  - dogs
KW  - neutrophils
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-129998
VL  - 7
IS  - 5
ER  - 
TY  - JOUR
A1  - Ahmad, Ruhel
A1  - Wolber, Wanja
A1  - Eckardt, Sigrid
A1  - Koch, Philipp
A1  - Schmitt, Jessica
A1  - Semechkin, Ruslan
A1  - Geis, Christian
A1  - Heckmann, Manfred
A1  - Brüstle, Oliver
A1  - McLaughlin, John K.
A1  - Sirén, Anna-Leena
A1  - Müller, Albrecht M.
T1  - Functional Neuronal Cells Generated by Human Parthenogenetic Stem Cells
JF  - PLoS One
N2  - Parent of origin imprints on the genome have been implicated in the regulation of neural cell type differentiation. The ability of human parthenogenetic (PG) embryonic stem cells (hpESCs) to undergo neural lineage and cell type-specific differentiation is undefined. We determined the potential of hpESCs to differentiate into various neural subtypes. Concurrently, we examined DNA methylation and expression status of imprinted genes. Under culture conditions promoting neural differentiation, hpESC-derived neural stem cells (hpNSCs) gave rise to glia and neuron-like cells that expressed subtype-specific markers and generated action potentials. Analysis of imprinting in hpESCs and in hpNSCs revealed that maternal-specific gene expression patterns and imprinting marks were generally maintained in PG cells upon differentiation. Our results demonstrate that despite the lack of a paternal genome, hpESCs generate proliferating NSCs that are capable of differentiation into physiologically functional neuron-like cells and maintain allele-specific expression of imprinted genes. Thus, hpESCs can serve as a model to study the role of maternal and paternal genomes in neural development and to better understand imprinting-associated brain diseases.
KW  - methylation
KW  - derivation
KW  - blastocysts
KW  - pluripotent
KW  - differentiation
KW  - lines
KW  - brain development
KW  - in-vitro
KW  - mice
KW  - specification
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130268
VL  - 7
IS  - 8
ER  -